Genomic Characterization Reveals Infections and Silent Dissemination of Carbapenemase-Producing Klebsiella Oxytoca Complex Associated with ST2 Lineage in a Hospital Setting
- PMID: 40804599
- DOI: 10.1007/s00284-025-04424-6
Genomic Characterization Reveals Infections and Silent Dissemination of Carbapenemase-Producing Klebsiella Oxytoca Complex Associated with ST2 Lineage in a Hospital Setting
Abstract
Our aim was to investigate lineages and resistome of carbapenemase-producing Klebsiella oxytoca Complex (KoC) strains isolated from 2019 to 2022 from colonization and infection samples to evaluate their potential dissemination. This prospective study showed the presence of eight multidrug-resistant K. oxytoca ST2 strains harboring blaKPC-2, blaKPC-3, or blaIMP-8 genes among both colonized (n = 5) and infected (n = 3) patients isolated during this period. Genomic analysis revealed antimicrobial resistance genes, virulence loci, including kleboxymycin and yersiniabactin, highlighting their resistance and pathogenicity in clinical settings. CgSNP analysis revealed that five isolates, HA8pKo, HA10pKo, HA14pKo, HA21Ko and HA22pKo, were the same strain disseminating among colonized patients (n = 4) during two months in 2019. K. oxytoca HA8pKo, HA10pKo, HA14pKo, HA21Ko, and HA22pKo strains shared three replicon types (Col(pHAD28), IncM1, and IncFII (K) as well as the blaKPC-2 gene. The blaKPC-2 gene was contained in the IncFII (K) replicon (pDCVEA12-KPC) which harbored a mercury resistance (mer) gene locus. The silent dissemination of carbapenemase-producing KoC strains colonizing patients is a cause for concern, prompting questions about the most suitable approaches for asymptomatic patients to prevent the spread and potential outbreaks. Our findings reinforced the relevance of epidemiological surveillance programs to identify the reservoir of carbapenemase-producing strains.
© 2025. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Conflict of interest statement
Declarations. Conflict of interest: The authors have no conflicts of interest to declare. Ethical Approval: Patient’s confidentiality is maintained throughout the study, and the study did not carry any additional risk to the patients. Participation in the study did not interfere with the patient’s management. Ethical approval was given by the Ethics Committee of the Hospital Alemán of Buenos Aires.
Similar articles
-
Antimicrobial resistance and phylogenetic lineages of KPC-2-producing blood-borne Klebsiella pneumoniae subsp. pneumoniae from Kolkata, India during 2015-2024: Emergence of Klebsiella pneumoniae subsp. pneumoniae with blaKPC-2, blaNDM, and blaOXA-48-like triple carbapenemases.Microbiol Spectr. 2025 Aug 5;13(8):e0012625. doi: 10.1128/spectrum.00126-25. Epub 2025 Jun 12. Microbiol Spectr. 2025. PMID: 40503825 Free PMC article.
-
Characterization of a blaKPC-3-carrying plasmid in a clinical isolate of Klebsiella pneumoniae belonging to the emerging successful clone ST147.Microbiol Spectr. 2025 Jul;13(7):e0233824. doi: 10.1128/spectrum.02338-24. Epub 2025 May 23. Microbiol Spectr. 2025. PMID: 40407340 Free PMC article.
-
Plasmid diversity in Klebsiella pneumoniae ST307 co-producing KPC plus NDM recovered during the COVID-19 pandemic.Infect Genet Evol. 2025 Sep;133:105795. doi: 10.1016/j.meegid.2025.105795. Epub 2025 Jul 8. Infect Genet Evol. 2025. PMID: 40639556
-
Outbreak of Klebsiella pneumoniae carbapenemase-producing K pneumoniae: A systematic review.Am J Infect Control. 2016 Nov 1;44(11):1374-1380. doi: 10.1016/j.ajic.2016.03.022. Epub 2016 May 5. Am J Infect Control. 2016. PMID: 27156198
-
Prevalence of carbapenemase genes in Klebsiella pneumoniae and Escherichia coli isolated from intensive care unit patients in Iran: a systematic review (2014-2025).Mol Biol Rep. 2025 Jul 1;52(1):660. doi: 10.1007/s11033-025-10774-y. Mol Biol Rep. 2025. PMID: 40590995 Review.
References
-
- Neog N, Phukan U, Puzari M et al (2021) Klebsiella oxytoca and emerging nosocomial infections. Curr Microbiol 78:1115–1123 - PubMed
-
- Vergara-López S, Domínguez MC, Conejo MC et al (2015) Lessons from an outbreak of metallo-β-lactamase-producing Klebsiella oxytoca in an intensive care unit: the importance of time at risk and combination therapy. J Hosp Infect 89:123–131. https://doi.org/10.1016/j.jhin.2013.12.008 - DOI - PubMed
-
- Wang J, Yuan M, Chen H et al (2017) First report of Klebsiella oxytoca strain simultaneously producing NDM-1, IMP-4, and KPC-2 carbapenemases. Antimicrob Agents Chemother 61:1–5
-
- Yang J, Long H, Hu Y et al (2022) Klebsiella oxytoca Complex: Update on Taxonomy, Antimicrobial Resistance, and Virulence. Clin. Microbiol, Rev, p 35
-
- Knecht CA, García Allende N, Álvarez VE et al (2022) Novel insights related to the rise of KPC-producing enterobacter cloacae complex strains within the nosocomial niche. Front Cell Infect Microbiol 12:1–11. https://doi.org/10.3389/fcimb.2022.951049 - DOI
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous